Abstract:Abstract Clinical question Recent 15-year updates of sigmoidoscopy screening trials provide new evidence on the effectiveness of colorectal cancer screening. Prompted by the new evidence, we asked: “Does colorectal cancer screening make an important difference to health outcomes in individuals initiating screening at age 50 to 79? And which screening option is best?” Current practice Numerous guidelines recommend screening, but vary on recommended test, age and screening frequency. This guideline looks at the evidence and makes recommendations on screening for four screening options: faecal immunochemical test (FIT) every year, FIT every two years, a single sigmoidoscopy, or a single colonoscopy. Recommendations These recommendations apply to adults aged 50-79 years with no prior screening, no symptoms of colorectal cancer, and a life expectancy of at least 15 years. For individuals with an estimated 15-year colorectal cancer risk below 3%, we suggest no screening (weak recommendation). For individuals with an estimated 15-year risk above 3%, we suggest screening with one of the four screening options: FIT every year, FIT every two years, a single sigmoidoscopy, or a single colonoscopy (weak recommendation). With our guidance we publish the linked research, a graphic of the absolute harms and benefits, a clear description of how we reached our value judgments, and linked decision aids. How this guideline was created A guideline panel including patients, clinicians, content experts and methodologists produced these recommendations using GRADE and in adherence with standards for trustworthy guidelines. A linked systematic review of colorectal cancer screening trials and microsimulation modelling were performed to inform the panel of 15-year screening benefits and harms. The panel also reviewed each screening option’s practical issues and burdens. Based on their own experience, the panel estimated the magnitude of benefit typical members of the population would value to opt for screening and used the benefit thresholds to inform their recommendations. The evidence Overall there was substantial uncertainty (low certainty evidence) regarding the 15-year benefits, burdens and harms of screening. Best estimates suggested that all four screening options resulted in similar colorectal cancer mortality reductions. FIT every two years may have little or no effect on cancer incidence over 15 years, while FIT every year, sigmoidoscopy, and colonoscopy may reduce cancer incidence, although for FIT the incidence reduction is small compared with sigmoidoscopy and colonoscopy. Screening related serious gastrointestinal and cardiovascular adverse events are rare. The magnitude of the benefits is dependent on the individual risk, while harms and burdens are less strongly associated with cancer risk. Understanding the recommendation Based on benefits, harms, and burdens of screening, the panel inferred that most informed individuals with a 15-year risk of colorectal cancer of 3% or higher are likely to choose screening, and most individuals with a risk of below 3% are likely to decline screening. Given varying values and preferences, optimal care will require shared decision making.

Interpretation of Updated Guidelines for Colorectal Cancer Screening in Average-Risk Individuals in the United States

CSCO Guidelines for Colorectal Cancer Version 2024: Updates and Discussions.

[Influence of Age on Advanced Neoplasia Detection in Colorectal Cancer Screening in Population at High Risk].

[Systematic review of the methodology quality and reporting quality in colorectal cancer screening guidelines].

[Quality assessment of global guidelines on colorectal cancer screening].

[Analysis of Community Colorectal Cancer Screening in 50-74 Years Old People in Guangzhou, 2015-2016].

Update in Version 2021 of CSCO Guidelines for Colorectal Cancer from Version 2020

Recent American College of Physicians Guidance Statement for Screening Average-risk, Asymptomatic Adults for Colorectal Cancer

Screening Methods for Colorectal Cancer in Chinese Populations.

Updates in Version 2019 of CSCO Guidelines for Colorectal Cancer from Version 2018.

Chinese national clinical practice guidelines on prevention, diagnosis and treatment of early colorectal cancer

Comparison of Colonoscopy, Fecal Immunochemical Test, and Risk-Adapted Approach in a Colorectal Cancer Screening Trial (TARGET-C)

Meta-analysis of the Compliance of Colorectal Cancer Screening in China ,2006～2015

Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a clinical practice guideline

[China National Lung Cancer Screening Guideline with Low-dose Computed Tomography (2018 Version)].

[Primary Evaluation of a Mass Screening Program for Colorectal Tumor in China].

China National Lung Cancer Screening Guideline with Low-Dose Computed Tomography (2015 Version)

Incidence, mortality, survival, risk factor and screening of colorectal cancer: A comparison among China, Europe, and northern America

[China National Lung Cancer Screening Guideline with Low-dose Computed Tomography (2023 Version)]

Colorectal Cancer Screening in a Changing World

Colorectal Cancer Screening With High Risk-Factor Questionnaire and Fecal Immunochemical Tests Among 5, 947, 986 Asymptomatic Population: A Population-Based Study